Shanghai, China –On April 21, Zhexiong Wang, Head of Department of Medical Device Registration of China Food and Drug Administration ("CFDA"), Lai Xu, Deputy Head of Shanghai Food and Drug Administration, and their team visited Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") to review the development of MicroPort®'s innovative medical device. MicroPort® Chairman and Chief Executive Officer Dr. Zhaohua Chang and Yimin Xu, Executive Vice President of Regulatory Affairs and Property Management received the team.
The team was shown around MicroPort® Self-Experience Center and briefed MicroPort®'s technology innovation, product clinical application, and future development plan. They were impressed by MicroPort®'s innovation models such as the Innovation Reactor and "1+12+1" Shared Platforms.
In the following panel discussion, Yimin Xu introduced the market expansion and social value of MicroPort®'s innovative medical devices launched in the market as well as the current process and future plan of the medical devices under research. The two sides then exchanged ideas regarding the fast-track review and approval procedure of medical devices. Dr. Zhaohua Chang said, MicroPort® always keeps in mind that it is the sustainable ability to innovate that drives the company's future, and he offered proposals regarding the development of innovative medical device. Zhexiong Wang said, MicroPort® has strong innovation incentives, which is a positive sign for the development of China's medical device industry. Meanwhile, he added, the CFDA will continue to deepen the reform of the approval system of China's medical devices, to promote the sustainable development of domestic enterprises' innovation abilities and support the innovation and development of the country's medical device industry.